Summary of Conference Call Notes Industry Overview - **Industry**: China Healthcare, specifically focusing on hospital equipment and medical devices - **Key Trends**: - July 2025 bidding value data showed a -11% month-over-month (MoM) decline, marking the third consecutive month of decrease, but a +23% year-over-year (YoY) increase was noted, indicating actual demand growth in hospitals [1][2] - The trade-in stimulus, deferred from 2024 to 2025, is expected to have a less pronounced effect compared to previous years [2] Company-Specific Insights United Imaging - **Management Outlook**: Optimistic about the new trade-in program in 2025, expecting a smoother process compared to 2024. However, revenue recognition cycles have lengthened due to changes in hospital bidding processes [19] - **Revenue Growth Projections**: Estimated growth rates for China revenue are +10% for 2Q25, +45% for 3Q25, and +26.8% for 4Q25. The DSA (imaging-guided therapy) product is identified as a near-term growth driver [21] - **Market Position**: Currently trading near median P/E multiple since listing, with significant long-term growth potential anticipated [21][88] Mindray - **Market Performance**: Slower YoY growth observed in patient monitors (+21% in July vs. +50% in June) and ultrasound (+24% in July vs. +48% in June) due to ASP pressure from VBP [26] - **Inventory Management**: Expected to normalize inventory turnover by 2Q25 across all segments [26] - **Investment Thesis**: Strong healthcare infrastructure and domestic substitution trends are expected to support growth. Trading below 5-year average forward P/E due to policy risks, but maintaining market leadership is anticipated [87] Key Data Points - **Bidding Value Trends**: - Positive YoY growth for nine consecutive months, with domestic brands outperforming MNCs [10] - Significant price declines in ultrasound and CT segments due to VBP, with ultrasound prices expected to remain under pressure [14] - **Procurement Value Changes**: - Ultrasound procurement value increased by +24% YoY in July, while CT scanners saw a +44% increase [45][47] - LINAC procurement value increased by +46% YoY in July, down from +161% in June [65] Risks and Challenges - **Market Risks**: - Ongoing regional VBPs are a key concern, with potential impacts on pricing and procurement processes [14] - Risks associated with chip supply chains, raw material availability, and macroeconomic downturns in China [92] Conclusion - The healthcare equipment industry in China is experiencing a complex landscape with both growth opportunities and challenges. Domestic companies like United Imaging and Mindray are positioned to benefit from favorable trends, although they must navigate pricing pressures and changing procurement dynamics.

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: The conference call primarily discusses the healthcare sector in China, particularly the medical technology (Medtech), in vitro diagnostics (IVD), retail pharmacies, hospitals, vaccines, and insulin markets [1][2]. Core Insights and Arguments Medtech - **Key Areas of Focus**: 1. Progress of capital equipment value-based procurement (VBP) and the trade-in policy [1] 2. Channel destocking trends [1] 3. Import substitution trends post-VBP, including intraocular lenses (IOLs) and IVD [1] - **VBP Impact**: The June bidding value data showed a year-on-year growth rate of 49%, but a month-on-month decline of 3%, indicating lower unit prices due to VBP [10]. IVD Market - **Weak Demand**: The IVD sector continues to face challenges, with a projected 20% year-on-year decline in the CLIA reagent market size for 2025 [19]. - **AmoyDx Performance**: AmoyDx is expected to grow against the trend due to its strong presence in compliant in-hospital sales channels, benefiting from the anti-corruption campaign [21]. Insulin Market - **Domestic Substitution**: The insulin industry has seen significant growth, particularly for insulin analogs from companies like Gan & Lee and THDB, which reported rapid revenue growth in 1Q25 [22]. Retail Pharmacies - **Market Pressure**: Retail pharmacies are under pressure due to strict reimbursement policies and weak consumer spending. However, there is a potential market-clearing trend expected by year-end [31]. Hospitals - **New Product Feedback**: Hospitals are seeing new product introductions, such as the new version of SMILE surgery and new PIOL products, which are expected to drive consumption recovery [1]. Vaccine Market - **Anti-Corruption Campaign**: The ongoing anti-corruption campaign within the CDC system is impacting vaccine demand and distribution channels [1]. Financial Performance and Estimates Earnings Revisions - **Mindray**: Annual earnings estimates revised down by 2.1% to 5.0% for 2025E-27E due to industry headwinds in medical equipment and IVD [2][37]. - **United Imaging**: Revenue and earnings forecasts adjusted down to reflect lower-than-expected bidding data [39]. - **SNIBE**: Earnings estimates revised down by 1.4% to 7.1% for 2025E-27E due to policy headwinds in the IVD sector [40]. Revenue Growth Expectations - **High Growth Companies**: THDB and Gan & Lee are expected to achieve the highest revenue growth due to a low base from VBP renewal in 2Q24 [6]. - **Mindray's Decline**: Mindray's China business is expected to decline by 26% year-on-year in 2Q25 due to IVD weakness [9]. Other Important Insights - **Trade-in Policy Concerns**: The trade-in stimulus fund is expected to run out, leading to a decline in applications and a reduced stimulus effect in the second half of 2025 [10]. - **Market Dynamics**: The healthcare market is experiencing a shift with increasing government support for procurement and a focus on innovative products [47][48]. Conclusion - The healthcare sector in China is facing various challenges, including policy headwinds, weak demand in certain segments, and the impact of ongoing reforms. However, there are also opportunities for growth, particularly in innovative products and domestic substitution trends. Companies like AmoyDx, Gan & Lee, and THDB are positioned to benefit from these trends, while others like Mindray and SNIBE are facing headwinds that may impact their performance in the near term.

Investment Rating - The report does not provide a specific investment rating for the EDA software industry or companies within it [1]. Core Insights - The US government has imposed restrictions on EDA software exports to China, requiring US EDA companies to obtain licenses for supplying to Chinese customers [1][2]. - The global EDA software market was valued at approximately USD 16 billion in 2024, with China's share increasing from 10% to around 15%, equating to about CNY 17-18 billion [5][6]. - The Chinese EDA market has experienced an annual growth rate of over 10% in recent years, driven by demand from AI and autonomous driving, but is expected to decline by approximately 10% year-on-year in 2025 due to the new restrictions [5][6]. - Global EDA suppliers currently dominate the Chinese market, accounting for 80-85% of the market share, with Synopsys and Cadence being the leading players [5][6]. Summary by Sections Current Updates and Impact of US EDA Software Restrictions - There are no detailed rules for the EDA software restrictions yet, and it may serve as a bargaining chip in US-China trade negotiations [5]. - US EDA companies have halted website access, software downloads, and technical support for Chinese customers, although existing authorized tools can still be used without updates [5]. Global/China EDA Market Size and Competition Landscape - The global EDA market was valued at around USD 16 billion in 2024, with China's market share rising to approximately 15% [5]. - Major players in the Chinese EDA market include Synopsys, Cadence, and Siemens' Mentor, with Synopsys leading in revenue, particularly in the IP business [5][6]. Progress of Domestic Substitution in China - Empyrean Technology is noted as a leading local player with comprehensive EDA product offerings, capable of replacing global solutions for analog ICs in 14nm+ processes [6]. - The domestic substitution process for advanced EDA software will take time, requiring cooperation across the semiconductor supply chain [6].

Group 1 - The core viewpoint is that supply-side reform, technological transformation, and overseas changes are the current focal points in the photovoltaic industry, which is experiencing a cash flow loss across the main chain and is at the bottom of the profit cycle [1] - The photovoltaic industry is expected to gradually recover due to enhanced expectations of supply-side reform, with policies aimed at controlling capacity growth and expanding demand to stabilize prices and return to reasonable profit levels [1] - The industry is transitioning from "scale expansion" to "quality first," focusing on high-quality development, energy consumption control, and technological innovation to accelerate industry clearing and promote stable development [1] Group 2 - The European commercial storage market is expected to see significant growth, with installed capacity projected to double from 2.7 GWh in 2024 to 5.4 GWh in 2025, and reach 19.5 GWh by 2028, reflecting a compound annual growth rate of 64% from 2024 to 2028 [2] - The demand for inverters is anticipated to increase during peak seasons, driven by the growth in commercial storage installations in Europe [2] Group 3 - Technological advancements such as BC, HJT, and copper paste are driving the industry forward, with companies like Aiko and Longi leading in BC technology, and the introduction of pure copper paste expected to accelerate the iteration of new technologies [3] - The price of silver paste constitutes over 50% of the non-silicon cost of batteries, making the development of silver reduction technologies a priority for major manufacturers [3] Group 4 - The photovoltaic industry has a high level of domestic production capacity, with significant progress in domestic quartz sand resources, which are crucial for the industry [4] - The discovery of high-purity quartz resources in regions like Henan and Xinjiang is expected to accelerate the domestic replacement of imported materials [4] Group 5 - Investment recommendations include focusing on the inverter segment due to stable demand and performance, with specific companies highlighted for potential investment [5] - Attention is also drawn to technological advancements in BC, HJT, and low-silver technologies, with several companies recommended for investment based on their progress in these areas [5] - The domestic replacement of quartz sand and the overseas battery capacity gap are additional areas of focus for investment opportunities [5]

Core Viewpoint - The electronic industry in China is experiencing sustained high growth, driven by policy benefits and demand recovery, with multiple sub-sectors showing significant investment potential [1][6]. Group 1: Industry Performance - The electronic industry achieved a total revenue of 3.46 trillion yuan in 2024, representing a year-on-year growth of 17.53%, ranking first among 31 major industries [4]. - Net profit for the electronic industry reached 134.41 billion yuan in 2024, with a year-on-year increase of 20.37% [4]. - In the first quarter of this year, the electronic industry maintained high growth, with total revenue of 859.45 billion yuan, up 17.82%, and net profit of 36.6 billion yuan, up 30.49% [4]. Group 2: Sub-sector Insights - The semiconductor and components sub-sectors continue to show strong profitability, with significant year-on-year growth in both revenue and net profit [4]. - The integrated circuit industry is experiencing rapid development driven by demand recovery, AI innovation, and domestic production [5]. Group 3: Market Dynamics - The industry is currently undergoing a threefold driving force: demand recovery from consumer electronics, a reasonable inventory cycle, and supply-side optimization through mergers and high-end strategies [5]. - The competitive landscape is improving, leading to higher average selling prices (ASP) and gross margins [5]. Group 4: Policy and Technological Advancements - The electronic industry is benefiting from policy support and technological breakthroughs, with companies focusing on independent research and development [6]. - Domestic manufacturers are transitioning from a manufacturing focus to independent R&D, with significant advancements in key technologies like AI chips and lithography machines [6]. Group 5: Future Outlook - The electronic industry is expected to maintain a positive growth trend, with advancements in AI applications and domestic chip production accelerating [7]. - The collaboration of policy support and technological innovation is likely to enhance the maturity of the domestic AI ecosystem, positioning China to lead global innovation cycles [7].

Investment Rating - The report maintains a "Buy" rating for both Mindray and United Imaging, indicating a positive outlook for their stock performance in the near future [82][83]. Core Insights - The procurement value of main medical devices in China has shown strong year-over-year (YoY) growth, with a month-over-month (MoM) increase of 13% in April, surpassing expectations [1]. - The report anticipates a high level of activity in medical equipment procurement throughout 2025, driven by government funding and a recovery in hospital demand [1][25]. - Mindray is expected to maintain its market leadership with multiple growth drivers, while United Imaging is projected to see significant long-term growth potential due to increasing service-related revenue [82][83]. Summary by Sections Procurement Trends - The total bidding value for nine main medical devices in China has reached a high level, with positive MoM growth observed in seven out of nine devices in March [26]. - The report notes that procurement activities are supported by government funding and the implementation of a trade-in program, which is expected to drive demand in the coming quarters [1][25]. Company Performance - Mindray's revenue growth is projected to be +10% in 2Q24, +40% in 3Q25, and +36.5% in 4Q25, reflecting a recovery in its end markets [9]. - United Imaging's management expressed optimism about the upcoming trade-in program in 2025, expecting a smoother process compared to 2024 [9]. Market Dynamics - The report highlights that both domestic and multinational companies achieved notable YoY growth in April, indicating a balanced competitive landscape in the medical device sector [64]. - The trend of domestic substitution is not particularly evident, as both local and multinational companies are performing well in the procurement market [64].